These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18191950)

  • 21. [Anti-HIV drugs].
    Raffi F
    Rev Prat; 1999 Oct; 49(16):1763-71. PubMed ID: 10578607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nature of equilibria and effects of drug treatments in some simple viral population dynamical models.
    Tuckwell HC; Wan FY
    IMA J Math Appl Med Biol; 2000 Dec; 17(4):311-27. PubMed ID: 11270747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV antiviral drug guide 1998.
    Whitfield L
    Posit Aware; 1998; 9(1):28, 30-42. PubMed ID: 11364998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV protease inhibitors: pharmacologic and metabolic distinctions.
    Sommadossi JP
    AIDS; 1999 Sep; 13 Suppl 1():S29-40. PubMed ID: 10546783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection.
    Armstrong-James D; Menon-Johansson A; Pozniak A
    AIDS; 2009 Apr; 23(7):865-7. PubMed ID: 19307940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periodic multidrug therapy in a within-host virus model.
    Browne CJ; Pilyugin SS
    Bull Math Biol; 2012 Mar; 74(3):562-89. PubMed ID: 21822766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily therapies.
    Carey D
    J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
    Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
    Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Part XV. Antiretroviral therapy for human immunodeficiency virus infection.
    Stephens JR; Rathbun RC; Lockhart SM; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2007 Nov; 100(11):417-24. PubMed ID: 18183858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.